Theravance Inc: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	47
ISBN Number	not applicable
Product Code	DAT09424

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

Theravance is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule medicines for the treatment of diseases including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Of its five programs in development, two are in late stage, its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas and its Beyond Advair collaboration with GSK.

The company's total revenues increased at a CAGR of 235% during 2002-2006, from $0.1 million to $20 million. This represents an absolute total growth of $19 million during the historical period. License, collaboration and other revenues including milestone and upfront payments contributed all of the company's revenues.

Theravance's total revenues are estimated to increase at a CAGR of 71% between 2006 and 2010, from $20 million to $168 million. Royalties on telavancin sales will be the major contributor to the company's total growth out to 2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Pipeline Products
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Theravance - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Theravance - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: Theravance - Key Facts
- Table 2: Theravance - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Theravance - Key Events Impacting Share Price Performance, 2002-2006
- Table 4: Theravance - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 5: Theravance - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: Theravance - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: Theravance - Cash Flow, 2002-2006 ($ Mn)
- Table 8: Theravance - Revenue Breakdown, 2002-2006 ($ Mn)
- Table 9: Theravance - in-house Pipeline Products
- Table 10: Theravance - Collaboration Pipeline
- Table 11: Theravance - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 12: Theravance - Key Competitors
- Table 13: Theravance - Key Suppliers
- Table 14: Theravance - Key Clients
- Table 15: Theravance - Key Shareholders
- Table 16: Theravance - SWOT Analysis Summary
- Table 17: Theravance - Value Chain Analysis
- Table 18: Theravance - Scorecard
- Table 19: Theravance - Key Employees
- Table 20: Theravance - Financial and Operational Overview